Desmethylselegiline
Desmethylselegiline structure
|
Common Name | Desmethylselegiline | ||
|---|---|---|---|---|
| CAS Number | 18913-84-3 | Molecular Weight | 173.25 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C12H15N | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 9℃ | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 844(2) , 283-91, (2006) A method for the simultaneous determination of selegiline and its metabolite, desmethylselegiline, in human whole blood and urine is presented. The method, which combines a fiber-based headspace solid-phase microextraction (SPME) technique with gas chromatogr... |
|
|
Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.
Mech. Ageing Dev. 123(8) , 1065-79, (2002) The aging process is characterized by a decline in cellular functions of diverse systems of the body, including the neuroendocrine-immune network. One neuroendocrinological theory of aging is based on findings that the loss of hypothalamic neurotransmitter fu... |
|
|
Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
J. Neural Transm. Suppl. (72) , 165-73, (2007) (-)-Deprenyl is a selective irreversible inhibitor of MAO-B. The parent compound is responsible for the enzyme inhibitory effect, but its metabolites are also playing a role in the complex pharmacological activity of the substance. In the present studies male... |
|
|
P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Drug Metab. Pharmacokinet. 22(2) , 78-87, (2007) Although there is evidence in the literature of the participation of CYP2B6 in the metabolism of selegiline, it is not clear which other CYP isoforms contribute to its metabolism. The aim of this study was to investigate the P450 isozymes (CYPs) involved in t... |
|
|
Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Clin. Neuropharmacol. 23(1) , 22-7, (2000) The goal of this study was to examine the multiple-dose pharmacokinetics of selegiline and its metabolites desmethylselegiline, 1-methamphetamine, and 1-amphetamine after oral administration of selegiline HCl. Twelve healthy volunteers received 10 mg of seleg... |
|
|
Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.
J. Neural Transm. Gen. Sect. 117(6) , 695-8, (2010) Postulated cytoprotective action of (-)-deprenyl (D), (-)-desmethyl-deprenyl (DD) and (-)-deprenyl-N-oxide (DNO) on L-buthionine-(S,R)-sulfoximine (BSO) toxicity was investigated using in vitro cultures of serum-deprived A-2058 melanoma cells. BSO (10 microM/... |
|
|
Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man.
Xenobiotica 32(9) , 823-31, (2002) 1. The metabolism of selegiline (SG) has been studied by investigating the time-course of urinary excretion of SG and its metabolites using high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) in combination with solid-... |
|
|
Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Eur. J. Clin. Pharmacol. 58(4) , 259-63, (2002) The aim of this study was to investigate the effect of hormone-replacement therapy (HRT) on the pharmacokinetics of the selective monoamine oxidase B inhibitor selegiline and its primary metabolites desmethylselegiline and l-metamphetamine.In this randomised,... |
|
|
Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa.
Med. Hypotheses 54(5) , 814-24, (2000) The paper provides an interdisciplinary evaluation of the etiology, pathogenesis, and experimental treatments of retinitis pigmentosa (RP). It addresses a 10-year controversy concerning the rate of progression of RP. One laboratory has estimated remaining vis... |
|
|
Neuroprotection for Parkinson's disease: prospects and promises.
Ann. Neurol. 53 Suppl 3 , S1-2, (2003)
|